The Federal Circuit has affirmed a district court judgment finding that Purdue Pharma’s patent claims to crush-resistant and low-toxicity OxyContin were invalid as obvious. The case involves patents related to Purdue’s formulation of extended-rel… Read More

Patents are a form of intellectual property – an asset. However, the value of that asset can be uncertain. As the European Patent Office (EPO) explains, Methods of evaluating patents for business purposes can be divided into quantitative and qualit… Read More

The Federal Circuit has vacated and remanded a decision by the Patent Trial and Appeal Board (PTAB or Board), finding that Palo Alto Networks failed to establish that certain claims of Centripetal Networks patents were unpatentable as obvious. The co… Read More

The Federal Circuit recently issued two precedential decisions in patent cases. In Galderma Laboratories v. Lupin, the court affirmed a district court’s decision that Lupin’s abbreviated new drug application (ANDA) did not infringe Galderma’s t… Read More

The Federal Circuit has granted a motion by Twitter, Inc., which operates the social media website now known as “X,” for summary affirmance of a lower court’s dismissal of VidStream’s attempt to obtain a preliminary injunction in a patent inf… Read More

At CHIP LAW GROUP, innovation isn’t just a buzzword—it’s our DNA. We’re thrilled to announce our standout performance in the latest Patexia Patent Intelligence Report, solidifying our position as a leading intellectual property an… Read More

The Federal Circuit has upheld a Patent Trial and Appeal Board (PTAB or Board) ruling that certain claims of US Patent No. 10,561,170 were invalid for anticipation. The court also upheld the Board’s denial of the patent owner’s proposed substitut… Read More

The European Patent Office (EPO) has announced that, as part of the European Union’s latest sanctions against Russia, it will refuse all patent requests filed by Russian nationals or companies with ties to Russia. All requests filed since July 10,… Read More